Marsh & McLennan Companies (MMC)
(Delayed Data from NYSE)
$219.10 USD
+0.86 (0.39%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $219.11 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$219.10 USD
+0.86 (0.39%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $219.11 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Zacks News
Growing Cyber Crime Presents New Opportunity for Insurers
by Sapna Bagaria
A new market opportunity, cyber insurance, is providing insurers enough scope of growth.
Marsh & McLennan (MMC) Gets Rating Actions, Outlook Down
by Zacks Equity Research
Moody's affirms the ratings of Marsh & McLennan (MMC). The outlook for the same changes to negative.
Marsh & McLennan to Buy Jardine Lloyd for Portfolio Boost
by Zacks Equity Research
Marsh & McLennan (MMC) okays Jardine Lloyd's acquisition to enrich capabilities and drive overall growth.
Marsh & McLennan's (MMC) Unit Launches Advisory Offering
by Zacks Equity Research
Marsh & McLennan's (MMC) arm extends advisory offering to guide users through InsurTech market.
The Zacks Analyst Blog Highlights: Petrobras, Enterprise Products, Marsh & McLennan, Carnival and Valero
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Petrobras, Enterprise Products, Marsh & McLennan, Carnival and Valero
Top Analyst Reports for Petrobras, Enterprise Products and Marsh & McLennan
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Petrobras (PBR), Enterprise Products Partners (EPD) and Marsh & McLennan (MMC)
Marsh & McLennan's Unit to Buy Summit and Pavilion
by Zacks Equity Research
Marsh & McLennan's (MMC) unit Mercer to buy Summit and Pavilion for its consulting business.
Marsh & McLennan's (MMC) Q2 Earnings Miss Estimates, Up Y/Y (revised)
by Zacks Equity Research
Marsh & McLennan's (MMC) Q2 results suffer a rise in expenses, which outdoes revenue growth.
Marsh & McLennan's (MMC) Q2 Earnings Miss Estimates, Up Y/Y
by Zacks Equity Research
Marsh & McLennan's (MMC) Q2 results suffer a rise in expenses, which outdoes revenue growth.
Marsh & McLennan (MMC) Lags Q2 Earnings Estimates
by Zacks Equity Research
Marsh & McLennan (MMC) delivered earnings and revenue surprises of -0.90% and 0.50%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Marsh & McLennan's (MMC) Q2 Earnings Miss, Revenue in Line
by Zacks Equity Research
Marsh & McLennan's (MMC) Q2 results suffered from a rise in expense that outpaced revenue growth.
Insurance Stocks' Earnings Due on Jul 26: CINF, HIG & More
by Zacks Equity Research
Benign catastrophe loss, strong operating environment and a solid capital position favor insurers this earnings season.
Aon's (AON) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Aon (AON)'s second-quarter earnings is likely to benefit from its strategic investments and a better portfolio mix.
Can Marsh & McLennan (MMC) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
Marsh & McLennan (MMC) is likely to ride high in Q2 on the back of robust revenues.
Marsh & McLennan Arm Buyout to Boost Construction Abilities
by Zacks Equity Research
Marsh & McLennan's (MMC) arm ramps up the company's inorganic growth profile to upgrade construction capabilities in Minnesota, upper Midwest and the Washington DC region.
Marsh & McLennan's Arm Inks Deal to Buy Wortham Insurance
by Zacks Equity Research
Marsh & McLennan's (MMC) arm to acquire independent insurance brokerage firm Wortham Insurance and widen its base in Texas.
Why Is Marsh & McLennan (MMC) Down 1.5% Since its Last Earnings Report?
by Zacks Equity Research
Marsh & McLennan (MMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
6 Reasons to Hold Marsh & McLennan (MMC) in Your Portfolio
by Zacks Equity Research
Marsh & McLennan (MMC) emerges as a prudent pick for investors' portfolio as the stock assures better returns, banking on six factors.
Willis Towers (WLTW) Q1 Earnings Surpass, Guidance Intact
by Zacks Equity Research
Willis Towers (WLTW) Q1 displays better performance across all its segments.
Top Research Reports for Texas Instruments, Union Pacific & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Union Pacific (UNP) and Mondelez (MDLZ).
Marsh & McLennan (MMC) Beats Q1 Earnings and Revenues
by Anupama Mukhopadhyay
Marsh & McLennan came out with adjusted earnings of $1.38 per share, which beat the Zacks Consensus Estimate of $1.30.
Can Marsh & McLennan (MMC) Q1 Earnings Beat on Revenues?
by Zacks Equity Research
Higher revenues backed by a solid segmental performance might aid Marsh & McLennan (MMC) to beat on earnings in Q1.
Top Research Reports for Facebook, UnitedHealth & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).
Marsh & McLennan Joins EEA to Further Blockchain Adoption
by Zacks Equity Research
Marsh & McLennan's (MMC) unit joins the EEA to further the adoption of blockchain technology application.
eHealth (EHTH) Q4 Loss Narrower Than Expected, View Revised
by Zacks Equity Research
eHealth???s (EHTH) Q4 reflects soft performance at Individual, Family and Small Business segment and higher costs weighing on the stock.